



Anti-human PRAME

130711BB



FOR RESEARCH ONLY! NOT FOR HUMAN USE!

| | |
|--------------------|----------------------------|
| Cat.-no.: | 102-PA28 |
| Size: | 200 µg |
| Lot. No.: | According to product label |
| Country of origin: | Germany |

Preparation: Produced from sera of rabbits pre-immunized with highly pure (>95%) recombinant human PRAME C-terminal end (Met321-Asn509) from *E. coli*.

Target Background

| | |
|------------------|--|
| Synonyms: | Melanoma antigen preferentially expressed in tumors; Opa-interacting protein 4; MAPE, OIP4 |
|------------------|--|

PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or „preferentially expressed antigen in melanoma”, was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind *Neisseria gonorrhoeae* opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein), although the functional implications of the interaction are unknown.

References

- Ikeda H et al, *Immunity* 1997, 6:199–208
- Haqq C et al, *Proc Natl Acad Sci USA* 2005, 102:6092
- Williams JM et al, *Mol Microbiol* 1998, 27:171–186
- Nakamura Y et al, *Ann Surg Oncol* 2007, 14:885–892

Database References Antigen

| | |
|------------------------|-------------|
| Protein RefSeq: | NP_006106.1 |
| Uniprot ID: | P78395 |
| mRNA RefSeq: | NM_006115.3 |

Product Specifications

| | |
|---------------------------|--|
| Species reactivity | human |
| Clone/Ab feature | rabbit IgG |
| Cross reactivity | ND |
| Host | rabbit |
| Clonality | polyclonal |
| Purification | Protein A purified |
| Immunogen | Recombinant human PRAME (<i>E. coli</i>) (Met321-Asn509) |
| Formulation | lyophilized |
| Buffer | PBS |

Stability: The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2–8°C. Frozen aliquots are stable for at least 6 months when stored at –20°C.

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1–1.0 mg/ml.



AVOID REPEATED FREEZE AND THAW CYCLES!

Applications

| | |
|----------------------|-----------------|
| Western Blot: | Use 1–5 µg/ml |
| ELISA: | Use 0,1–1 µg/ml |

NOTE: OPTIMAL DILUTIONS SHOULD BE DETERMINED BY EACH LABORATORY FOR EACH APPLICATION!



Anti-human PRAME

Handling/Applications




Figure 1: Western Analysis of anti-human PRAME. Sample was loaded in 21% SDS-polyacrylamide gel under reducing conditions. Lane 1: MWM (kDa); lane 2: rh PRAME.




Fig. 2: ELISA using the polyclonal rabbit anti-human PRAME as detection antibody and the recombinant human PRAME fragment (ER #400-016) as standard.